Volunteers are needed for a new drug trial looking to reduce or prevent the onset of severe symptoms of a COVID-19 infection.
What are we studying? This study is looking to see if an investigational drug called RTB101 has the potential to prevent or lessen the effects of COVID-19. RTB101 is an investigational drug that is not approved for use in any indication by health regulators, including the United States Food and Drug Administration (FDA). Participants will take the study drug for two weeks and be monitored for one additional week afterward.
What is involved?
Telephone Contact
- Research staff will only contact you by phone for this study. Contact will include screening, and twice weekly calls for three weeks.
Study Medication
- You will be randomly assigned to receive RTB101 or a placebo pill, which you will take once daily for 2 weeks (14 days)
Electronic Symptom Diary
- You will be asked to fill out an electronic diary for three weeks.
Who is eligible?
If you are age 65 or older and have had a positive COVID-19 test result in the last 4 days but currently have no COVID-19 symptoms OR If you have recently been exposed to someone living in your household who has a positive COVID19 test you may qualify.
If you are interested in participating in this study or if you would like more information, please call toll free (844) 925-8500. This is an NIH funded study in collaboration with UConn Center on Aging, The Marcus Institute at Hebrew SeniorLife, Harvard Medical School affiliate, and resTORbio.
For more information on what is involved, view the COVID-19 RTB101 study video.
For more information, contact: Lisa Kenyon-Pesce at Kenyon-Pesce@uchc.edu